Edwards Lifesciences is a leading global structural heart medical device company that develops and sells minimally invasive treatments for cardiovascular diseases, the leading cause of death worldwide. The company's core business centers on three product groups: transcatheter aortic valve replacement therapies (primarily the SAPIEN valve family), transcatheter mitral and tricuspid valve therapies (including the PASCAL and EVOQUE systems), and surgical structural heart products (featuring tissue valves like INSPIRIS RESILIA). Edwards generates revenue by selling these devices to hospitals and healthcare providers across more than 100 countries, with a geographically diverse customer base spanning the United States, Europe, Japan, and other markets, and earns money through device sales driven by procedure adoption and patient volume.